PriceTargets.com logo

180 Life Sciences - ATNF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.22 As of 12/27/2024 01:06 PM ET
▼ -0.61 (-21.55%)

This chart shows the closing price for ATNF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 180 Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATNF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATNF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for 180 Life Sciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.22.

This chart shows the closing price for ATNF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in 180 Life Sciences. This rating has held steady since October 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/20/2022Alliance Global PartnersInitiated CoverageBuy
5/9/2022Maxim GroupDowngradeBuy ➝ Hold
9/15/2021Maxim GroupInitiated CoverageBuy$4,180.00
(Data available from 12/27/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
180 Life Sciences logo
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $2.22
Low: $2.10
High: $2.61

50 Day Range

MA: $2.82
Low: $1.74
High: $5.03

52 Week Range

Now: $2.22
Low: $1.16
High: $17.75

Volume

372,951 shs

Average Volume

790,159 shs

Market Capitalization

$2.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.12

Frequently Asked Questions

What sell-side analysts currently cover shares of 180 Life Sciences?

The following equities research analysts have issued stock ratings on 180 Life Sciences in the last year:
View the latest analyst ratings for ATNF.

What is the current price target for 180 Life Sciences?

0 Wall Street analysts have set twelve-month price targets for 180 Life Sciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for 180 Life Sciences in the next year.
View the latest price targets for ATNF.

What is the current consensus analyst rating for 180 Life Sciences?

180 Life Sciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ATNF.

What other companies compete with 180 Life Sciences?

Other companies that are similar to 180 Life Sciences include CERo Therapeutics, NLS Pharmaceutics, Eagle Pharmaceuticals, Evoke Pharma and Eyenovia. Learn More about companies similar to 180 Life Sciences.

How do I contact 180 Life Sciences' investor relations team?

180 Life Sciences' physical mailing address is 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007. The company's listed phone number is (650) 507-0669 and its investor relations email address is [email protected]. The official website for 180 Life Sciences is www.kblmerger.com. Learn More about contacing 180 Life Sciences investor relations.